Clinical Trial

F573 for Injection for the Treatment of Liver Injury/Failure

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury (DILI), chronic hepatitis B (CHB), intrahepatic cholestatic liver injury, etc.).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-01-09; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2024-02-07
Trial Details
NCT Number NCT05689645
Lead Sponsor Beijing Continent Pharmaceutical Co, Ltd.
Conditions Acute Liver Failure, Acute-On-Chronic Liver Failure
Enrollment 97 participants
Start Date 2023-03-24
Primary Completion 2026-09-01 (estimated)
Study Completion 2026-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-19